Items where authors include "Valle, JW"
Article
McNamara, MG, Swain, J, Craig, Z et al. (21 more authors) (2023) NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. eClinicalMedicine, 60. 102015. ISSN 2589-5370
Abed Abud, A, Abi, B, Acciarri, R et al. (1225 more authors) (2022) Separation of track- and shower-like energy deposits in ProtoDUNE-SP using a convolutional neural network. European Physical Journal C, 82 (10). 903. ISSN 1434-6044
Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22 (7). e288-e289. ISSN 1470-2045
Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 22 (5). pp. 690-701. ISSN 1470-2045
Jones, CM, Radhakrishna, G, Aitken, K et al. (15 more authors) (2020) Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 123 (5). pp. 709-713. ISSN 0007-0920
Abi, B, Acciarri, R, Acero, MA et al. (965 more authors) (2020) DUNE Far Detector Technical Design Report, Volume I. Introduction to DUNE. Journal of Instrumentation, 15 (8). ARTN T08008. ISSN 1748-0221
Corrie, PG, Qian, W, Basu, B et al. (31 more authors) (2020) Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122. pp. 1760-1768. ISSN 0007-0920
Craig, Z orcid.org/0000-0001-9930-6648, Swain, J, Batman, E et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055
Jones, RP, Psarelli, E-E, Jackson, R et al. (38 more authors) (2019) Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surgery, 154 (11). pp. 1038-1048. ISSN 2168-6254
Primrose, JN, Fox, RP, Palmer, DH et al. (26 more authors) (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20 (5). pp. 663-673. ISSN 1213-9432
Backen, AC, Lopes, A, Wasan, H et al. (16 more authors) (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 119 (1). pp. 27-35. ISSN 0007-0920
Elander, NO, Aughton, K, Ghaneh, P et al. (25 more authors) (2018) Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118 (8). pp. 1084-1088. ISSN 0007-0920
Elander, NO, Aughton, K, Ghaneh, P et al. (25 more authors) (2018) Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 118 (7). pp. 947-954. ISSN 0007-0920
Neoptolemos, JP, Palmer, DH, Ghaneh, P et al. (31 more authors) (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, 389 (10073). pp. 1011-1024. ISSN 0140-6736
Proceedings Paper
McNamara, MG, Swain, J, Craig, Z et al. (11 more authors) (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .